Literature DB >> 17056361

Idiopathic macular hole surgery with low-concentration infracyanine green-assisted peeling of the internal limiting membrane.

Paolo Lanzetta1, Antonio Polito, Michele Del Borrello, Raja Narayanan, Vinay A Shah, Antonio Frattolillo, Francesco Bandello.   

Abstract

PURPOSE: To evaluate the efficacy of pars plana vitrectomy with infracyanine green (IFCG)-assisted internal limiting membrane peeling for the treatment of idiopathic macular hole.
DESIGN: Prospective, noncomparative interventional case series.
METHODS: Thirty-eight consecutive eyes of 35 patients with idiopathic macular hole were included in the study. Patients underwent early treatment diabetic retinopathy (ETDRS) visual acuity examination, dilated ophthalmoscopy, and optical coherence tomography before treatment and during follow-up. Fluorescein angiography was done in selected cases. Patients underwent a three-port pars plana vitrectomy with complete posterior hyaloid and epiretinal membrane removal. The internal limiting membrane (ILM) was stained with 0.5 cc of IFCG (0.5 mg/ml, 308 mOsm) and peeled up to the vascular arcades. Perfluoropropane gas (C(3)F(8)) 10% was used as tamponade.
RESULTS: Mean follow-up duration was 10 +/- 5 months (range, 3 to 24 months). Six eyes had stage 2 macular hole, 15 eyes stage 3, and 16 eyes stage 4. Overall, 37 of 38 macular holes closed after a single surgery. Median visual acuity was 20/100 (range, 20/400 to 20/50) before surgery and 20/50 (range, 20/640 to 20/25) after surgery. Visual acuity after surgery was 20/50 or better in 24 of 38 (63.1%) eyes. Twenty-five (65.8%) eyes improved by 2 or more lines, nine (23.7%) eyes were stable, and four (10.5%) eyes worsened by 2 or more lines.
CONCLUSIONS: This study suggests that IFCG (0.05%) effectively stains the ILM with apparent safety, and that IFCG-assisted peeling of the ILM may be useful in the treatment of idiopathic macular hole.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056361     DOI: 10.1016/j.ajo.2006.06.032

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Synthesis, staining properties, and biocompatibility of a new cyanine dye for ILM peeling.

Authors:  Christos Haritoglou; Marcus Kernt; Peter Laubichler; Heinz Langhals; Kirsten Eibl; Ana Varja; Sebastian Thaler; Anselm Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-23       Impact factor: 3.117

2.  Tempol protects against intravitreous indocyanine green-induced retinal damage in rats.

Authors:  Sebastian Thaler; Bogomil Voykov; Gabriel Willmann; Michal Fiedorowicz; Robert Rejdak; Florian Gekeler; C Albrecht May; Andreas Schatz; Frank Schuettauf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-31       Impact factor: 3.117

Review 3.  Iatrogenic retinal traumas in ophthalmic surgery.

Authors:  Daniele Tognetto; Maria Teresa di Lauro; Daniela Fanni; Adelia Zagidullina; Luca Michelone; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-05       Impact factor: 3.117

Review 4.  Complications of Macular Peeling.

Authors:  Mónica Asencio-Duran; Beatriz Manzano-Muñoz; José Luis Vallejo-García; Jesús García-Martínez
Journal:  J Ophthalmol       Date:  2015-09-03       Impact factor: 1.909

Review 5.  Chromovitrectomy: an update.

Authors:  Flora Hernández; Natalia Alpizar-Alvarez; Lihteh Wu
Journal:  J Ophthalmic Vis Res       Date:  2014-04

6.  Surgical results of internal limiting membrane flap inversion and internal limiting membrane peeling for macular hole.

Authors:  Hiroya Ota; Hiroshi Kunikata; Naoko Aizawa; Toru Nakazawa
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

7.  Infracyanine Green vs. Brilliant Blue G in Inverted Flap Surgery for Large Macular Holes: A Long-Term Swept-Source OCT Analysis.

Authors:  Salvatore Cillino; Massimo Castellucci; Giovanni Cillino; Valentina Sunseri; Costanza Novara; Francesco Di Pace; Maria Vadalà; Vincenza Bonfiglio; Alessandra Casuccio
Journal:  Medicina (Kaunas)       Date:  2020-01-20       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.